
    
      This is a Phase 3 randomized, placebo-controlled, double-blind multicenter study with
      approximately 110 subjects, aged 5 to < 18 years old. Subjects with documented Achondroplasia
      confirmed by genetic testing will have been enrolled in Study 111-901 for at least a 6-month
      period immediately before entering into the 111-301 study. Eligible subjects will be randomly
      assigned to one of two treatment groups: placebo or BMN 111 at 15 Î¼g/kg. The route of
      administration is subcutaneous injection and the frequency is daily.
    
  